These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8320424)

  • 1. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
    Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
    J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy.
    Gambacciani M; Spinetti A; Taponeco F; Ciaponi M; Cima GP; Teti GC; Genazzani AR
    Gynecol Endocrinol; 1995 Jun; 9(2):131-5. PubMed ID: 7502689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
    Gambacciani M; Spinetti A; Piaggesi L; Cappagli B; Taponeco F; Manetti P; Weiss C; Teti GC; La Commare P; Facchini V
    Bone Miner; 1994 Jul; 26(1):19-26. PubMed ID: 7950502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
    Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
    Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.
    Fioretti P; Gambacciani M; Taponeco F; Melis GB; Capelli N; Spinetti A
    Maturitas; 1992 Dec; 15(3):225-32. PubMed ID: 1465036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
    Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
    Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
    Gambacciani M; Ciaponi M; Cappagli B; Piaggesi L; Genazzani AR
    Maturitas; 1997 Sep; 28(1):75-81. PubMed ID: 9391998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
    Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
    Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
    Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
    Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
    Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
    JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
    Gambacciani M; Cappagli B; Piaggesi L; Ciaponi M; Genazzani AR
    Calcif Tissue Int; 1997; 61 Suppl 1():S15-8. PubMed ID: 9263611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
    Kovács AB
    Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
    Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
    Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
    Katase K; Kato T; Hirai Y; Hasumi K; Chen JT
    Calcif Tissue Int; 2001 Aug; 69(2):73-7. PubMed ID: 11683426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipriflavone for the treatment of osteoporosis.
    Choi YK; Han IK; Yoon HK
    Osteoporos Int; 1997; 7 Suppl 3():S174-8. PubMed ID: 9536327
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
    Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
    Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
    Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
    Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
    Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
    Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
    de Aloysio D; Gambacciani M; Altieri P; Ciaponi M; Ventura V; Mura M; Genazzani AR; Bottiglioni F
    Gynecol Endocrinol; 1997 Aug; 11(4):289-93. PubMed ID: 9272427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.